Avacta Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Scale Space White City Imperial College ...Phone Number
+44 2039110353Website
www.avacta.comRevenue
<$5 MillionStock Symbol
AVCTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Avacta Therapeutics
Avacta Therapeutics specializes in innovative cancer treatment solutions through its proprietary preCISION technology, which enables targeted drug delivery to tumors while minimizing systemic exposure. Their approach involves linking existing cancer drugs to a peptide that is activated only by a tumor-specific enzyme, allowing for precise treatment. The company aims to enhance the efficacy of cancer therapies while preserving patient wellness. Avacta Therapeutics primarily serves the oncology sector, focusing on improving outcomes for cancer patients.Explore more
Avacta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avacta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Avacta Therapeutics
Check if Avacta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Avacta Therapeutics is spiking on competitors!
Product Launch: Get notified when Avacta Therapeutics launches new products
Click to see if Avacta Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Avacta Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Avacta Therapeutics has new funding data
Avacta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Avacta Therapeutics
Compare insights from companies similar to Avacta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avacta Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Avacta Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Avacta Therapeutics.
Avacta Therapeutics financials insights
Gather financial insights about Avacta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$13.2M
Avacta Therapeutics Tech Stack
A closer look at the technologies used by Avacta Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Project
Avacta Therapeutics has reported that its AVA6103 exatecan molecule is set to enter clinical trials, with preclinical data showing optimized dosing allowing significantly higher peptide drug conjugate doses than conventional exatecan and at least five days tumor coverage through sustained release.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Bioengineering, Pharmaceuticals
Avacta Therapeutics News & Media
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call May 19, 2026 9:00 AM EDTCompany ParticipantsChristina Coughlin - CEO & Executive DirectorBrian Hahn - CFO...Unaudited Preliminary Results for the Year Ended December 31, 2025
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform
Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) Enhertu®
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Avacta Therapeutics
Sign Up For FreeTo access detailed company insights
Avacta Therapeutics specializes in innovative cancer treatment solutions through its proprietary preCISION technology, which enables targeted drug delivery to tumors while minimizing systemic exposure. Their approach involves linking existing cancer drugs to a peptide that is activated only by a tumor-specific enzyme, allowing for precise treatment... Read More
